TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $18 to $19.
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $18 to $19.